Updated continuously by citizens like you, Newsvine is an instant reflection of what the world is talking about at any given moment.
Article Source: Bloomberg.com
With OVER 1.25 BILLION** in judgements against J&J and/or the drugs developer Janssen, Respirdal (respirdone) remains one of the MOST PROLIFIC sales performers for its owners.
Who , BTW, buried negative study data, promoted their drug to children KNOWING its side effects were deadly and/or MUTAGENIC ...permanently.
Litigation Record
In 2010, the company lost a Risperdal case inLouisiana, where on top of a $257.7 million jury award the judge ordered the company to pay $73.3 million in attorneys’ fees and costs. A year later, a South Carolina judge ordered J&J to pay $327 million in damages after a jury found its Risperdal marketing practices violated fraud andconsumer protection laws.
J&J also has agreed to pay more than $1 billion to the U.S. and a number of states to end a civil probe into its Risperdal marketing practices, people familiar with the matter told Bloomberg News on Jan. 6.
The U.S. government has been investigating Risperdal sales practices since 2004, including allegations the company engaged in so-called off-label marketing of the medication, J&J has said in U.S. Securities and Exchange Commissionfilings. The company said it has been negotiating with the U.S. to resolve the investigation.
The New Jersey case is Skala v.Johnson & Johnson (JNJ), MID- L-6820-06 (MT), Superior Court of New Jersey, Law Division,Middlesex County(New Brunswick).
**OOPS corrected $1.658 BILLION in fines and judgements
#1 - Mon Feb 6, 2012 3:01 PM ESTYou're in Easy Mode. If you prefer, you can use XHTML Mode instead. |
Log In | Register
